Clinical Trial Update: sCD163 as a Potential Biomarker in Guillain- Barré Syndrome

View source ↗

Summary

A clinical trial update discusses the potential of sCD163 as a biomarker in Guillain-Barré syndrome in study NCT02582853.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Guillain-barré Syndrome

Snippet

Sponsor: University of Aarhus | Conditions: Guillain-Barre Syndrome | Status: UNKNOWN